R&G Pharmastudies Co.,Ltd.’s Net Profit Rose 39.4% in First Half of 2023

R&G Pharmastudies Co.,Ltd. (诺思格(北京)医药科技股份有限公司) (301333.SZ) reported a net profit of 86.4 million yuan in the first half of 2023, up 39.4% year-on-year.

Meanwhile, the company posted 361.9 million yuan in revenue, up 11% year-on-year.

At the end of the reporting period, it had 2 billion yuan in total assets and 294.8 million yuan in total liabilities, with a liability-to-asset ratio of 15%.